Cargando…

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor

Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakošek Pipan, Maja, Prpar Mihevc, Sonja, Štrbenc, Malan, Košak, Urban, German Ilić, Ilija, Trontelj, Jurij, Žakelj, Simon, Gobec, Stanislav, Pavlin, Darja, Majdič, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438013/
https://www.ncbi.nlm.nih.gov/pubmed/34518582
http://dx.doi.org/10.1038/s41598-021-97404-2
_version_ 1783752277901705216
author Zakošek Pipan, Maja
Prpar Mihevc, Sonja
Štrbenc, Malan
Košak, Urban
German Ilić, Ilija
Trontelj, Jurij
Žakelj, Simon
Gobec, Stanislav
Pavlin, Darja
Majdič, Gregor
author_facet Zakošek Pipan, Maja
Prpar Mihevc, Sonja
Štrbenc, Malan
Košak, Urban
German Ilić, Ilija
Trontelj, Jurij
Žakelj, Simon
Gobec, Stanislav
Pavlin, Darja
Majdič, Gregor
author_sort Zakošek Pipan, Maja
collection PubMed
description Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.
format Online
Article
Text
id pubmed-8438013
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84380132021-09-15 Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor Zakošek Pipan, Maja Prpar Mihevc, Sonja Štrbenc, Malan Košak, Urban German Ilić, Ilija Trontelj, Jurij Žakelj, Simon Gobec, Stanislav Pavlin, Darja Majdič, Gregor Sci Rep Article Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this. Nature Publishing Group UK 2021-09-13 /pmc/articles/PMC8438013/ /pubmed/34518582 http://dx.doi.org/10.1038/s41598-021-97404-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zakošek Pipan, Maja
Prpar Mihevc, Sonja
Štrbenc, Malan
Košak, Urban
German Ilić, Ilija
Trontelj, Jurij
Žakelj, Simon
Gobec, Stanislav
Pavlin, Darja
Majdič, Gregor
Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_full Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_fullStr Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_full_unstemmed Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_short Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
title_sort treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438013/
https://www.ncbi.nlm.nih.gov/pubmed/34518582
http://dx.doi.org/10.1038/s41598-021-97404-2
work_keys_str_mv AT zakosekpipanmaja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT prparmihevcsonja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT strbencmalan treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT kosakurban treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT germanilicilija treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT tronteljjurij treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT zakeljsimon treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT gobecstanislav treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT pavlindarja treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor
AT majdicgregor treatmentofcaninecognitivedysfunctionwithnovelbutyrylcholinesteraseinhibitor